Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alector

- PMLiVE

FDA advisory committee overwhelmingly votes no on Biogen’s aducanumab

Path to approval looks increasingly difficult for potential Alzheimer’s treatment

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

- PMLiVE

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

Study extends into additional sites after positive safety assessment

- PMLiVE

GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year

GSK is currently partnering with Sanofi on a COVID-19 vaccine project

- PMLiVE

FDA sets November date for expert panel review of Biogen’s aducanumab

Advisory committee will review biologics license application for controversial therapy

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

GSK doses first patients in phase 3 meningitis vaccine trial

Clinical programme will test five-in-one vaccine candidate

- PMLiVE

Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Drug could become first treatment to reduce clinical decline in Alzheimer's

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links